Capricor Therapeutics Inc Stock Nasdaq
Stocks
US14070B1017
Biotechnology & Medical Research
| Market Cap | 486M 427M 403M 367M 687M 46.58B 692M 4.82B 1.87B 23.8B 1.82B 1.79B 76.49B | P/E 2026 * |
-4.56x | P/E 2027 * | -5.61x |
|---|---|---|---|---|---|
| Enterprise Value | 486M 427M 403M 367M 687M 46.58B 692M 4.82B 1.87B 23.8B 1.82B 1.79B 76.49B | EV / Sales 2026 * |
8.73x | EV / Sales 2027 * | 8.6x |
| Free-Float |
90.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Capricor Therapeutics Inc
| 1 day | +10.01% |
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 62 | 20/11/2013 |
Anthony Bergmann
DFI | Director of Finance/CFO | 40 | 01/01/2018 |
Michael Binks
CTO | Chief Tech/Sci/R&D Officer | - | 13/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Litvack
CHM | Chairman | 70 | 01/11/2013 |
David Musket
BRD | Director/Board Member | 68 | 20/11/2013 |
George Dunbar
BRD | Director/Board Member | 79 | 20/11/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.01% | -11.80% | - | - | 486M | |
| -3.30% | +1.50% | +51.24% | +99.26% | 72.26B | |
| +1.25% | -3.01% | +40.12% | +77.12% | 60.24B | |
| +2.12% | +5.26% | +32.50% | +21.28% | 27.73B | |
| -3.06% | -1.81% | -13.10% | +357.06% | 25.74B | |
| -0.75% | +2.56% | +0.45% | -4.46% | 24.75B | |
| +0.40% | +0.75% | +22.91% | -9.68% | 20.74B | |
| -1.70% | -2.12% | +146.86% | +314.52% | 15.06B | |
| +0.36% | -0.34% | +50.32% | +166.42% | 14.42B | |
| +0.21% | +1.17% | -8.07% | +499.10% | 14.23B | |
| Average | +0.55% | +0.44% | +35.92% | +168.96% | 30.57B | |
| Weighted average by Cap. | -0.75% | +0.31% | +36.31% | +129.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 55.69M 48.87M 46.15M 42.06M 78.74M 5.34B 79.3M 552M 214M 2.73B 209M 205M 8.76B | 56.54M 49.61M 46.86M 42.7M 79.93M 5.42B 80.51M 561M 217M 2.77B 212M 208M 8.9B |
| Net income | -132M -116M -109M -99.68M -187M -12.65B -188M -1.31B -507M -6.46B -496M -485M -20.77B | -89.51M -78.54M -74.18M -67.6M -127M -8.58B -127M -888M -344M -4.38B -336M -329M -14.09B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
